Navigation Links
Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
Date:1/31/2008

ner Amgen Inc., were $856.0 million for the 2007 fourth quarter and $3,230.0 million for the 2007 full year, increases of 8% and 12% respectively, over the comparable prior periods. Wyeth has exclusive rights to Enbrel outside of the United States and Canada.

Enbrel is a breakthrough product approved for the treatment of chronic inflammatory diseases, including rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis. Enbrel is now the leading biotech product in total global sales, ranks fifth among the top pharmaceutical products globally by sales, and is among the top 10 best selling medicines in 13 countries. It is also the fastest growing of the top 10 pharmaceutical products.

In November 2007, data presented at the American College of Rheumatology showed strong clinical efficacy, as well as remission, for patients being treated for active early rheumatoid arthritis with Enbrel plus methotrexate compared to methotrexate alone, with 50 percent of patients achieving clinical remission at one year. These results were from the first major early rheumatoid arthritis clinical trial of a biologic to use clinical remission as a primary endpoint.

Prevnar(R), Wyeth's vaccine to prevent invasive pneumococcal disease in both infants and young children, continues to be the world's best-selling vaccine. In October 2007, Prevnar became the first vaccine to achieve $2.0 billion in annual global sales. Prevnar is available in 86 countries worldwide and is now included in 19 National Immunization Programs (NIPs), with six additional countries announcing intentions to initiate NIPs.

Effexor(R) (Effexor and Effexor XR) continues to be the number one global antidepressant in sales and prescription volume and an important therapy in treating adult patients with major depressive disorder, generalized anxiety disorder, social anxiety disorder and panic disorder.

Protonix(R) performed well again in
'/>"/>

SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
2. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
3. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
4. Wyeth Announces Election of New Principal Corporate Officer
5. Wyeth Declares Preferred Stock Dividend
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
8. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Texas , April 20, 2015 ... surgeons for healing bone injuries. The orthobiologics market is ... opportunities for its stakeholders. The global orthobiologics market report ... forecast of revenue. The global orthobiologics market was valued ... reach $7,900.2 million by 2019, at a CAGR of ...
(Date:4/20/2015)... , April 20, 2015  Eli Lilly and ... data from several targeted cancer therapies, reflecting Lilly,s diverse ... (AACR) Annual Meeting 2015, held April 18-22 in ... Cancer Discoveries to Patients" is the theme of this ... Lilly,s commitment to broadening its portfolio of therapies that ...
(Date:4/20/2015)... TORONTO , April 20, 2015 /CNW/ - Portage ... Canadian Securities Exchange: PBT.U), is pleased to announce that ... completed a collaborative research study that showed one of ... reduces inflammation in brain tissue through inhibition of NFkB ... The permeability of the blood brain ...
(Date:4/20/2015)... Global Stem Cells Group ... an annual gathering of aesthetic medicine experts and innovators. ... to introduce the company’s brand new training course that ... cell techniques. , The course is designed to ... aesthetic field, including facial aging caused by volume loss. ...
Breaking Biology Technology:Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 2Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 6Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 3Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 2Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 3
... STOCKHOLM, January 21 Richter-Helm,BioLogics GmbH & Co. ... for the development and manufacturing of Athera,s novel ... binding of the,protein, Annexin A5, to endothelium. The ... of patients with Acute Coronary Syndrome and who,are ...
... Pharmaceuticals, Inc. (NYSE Alternext US: IMM.BC) today announced ... Company, LLP as its independent registered public accounting ... Company,s independent registered public accounting firm was approved ... appointment will result in cost savings for Immtech. ...
... 20 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN ; ... Deficiency Letter on January 13, 2009, indicating that it ... set forth in Nasdaq Marketplace Rule 4350(c)(1) (the "Rule"). ... a Director, which was announced publicly in a January ...
Cached Biology Technology:Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease 2Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease 3Immtech Announces Appointment of Virchow Krause as Independent Registered Public Accounting Firm 2Vasogen Complies with NASDAQ Marketplace Rule 4350(c)(1) 2
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
(Date:4/10/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) ... Profiles - NEC" report to their offering. ... continue to supply a range of IT security management ... focus on the development of a Big Data and ... the Asia-Pacific region is a ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... University biologists are part of an international research team ... remote Arctic lake provides compelling evidence of unprecedented environmental ... "Our findings show that the last several decades have ... Neal Michelutti, a research scientist at the Paleoecological Environmental ...
... An analysis of sediment cores indicates that biological and chemical ... the past 200,000 years and likely are the result of ... the University of Colorado at Boulder. While environmental ... shown to be tightly linked with natural causes of climate ...
... new ways to fight cancer and other diseases have ... circadian rhythm, says Liheng Shi, a researcher in Texas ... the roughly 24-hour cycle of physiological activities of humans, ... have had their research, currently focusing on the circadian ...
Cached Biology News:Queen's scientists on international team discover 'ecologically unique' changes in Arctic lake 2Arctic lake sediments show warming, unique ecological changes in recent decades 2Arctic lake sediments show warming, unique ecological changes in recent decades 3Texas A&M researchers find new mechanism for circadian rhythm 2
Mouse Nodal Affinity Purified Polyclonal Ab...
Immunogen: Full length M32 fusion protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human TFPI Affinity Purified Polyclonal Ab Protein Family: Coagulation, Inflammation, Serine Protease Regulators...
Prostaglandin E2 Luminex Standard Product Lines: Unspecified...
Biology Products: